WO1999066909A3 - Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme - Google Patents

Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme Download PDF

Info

Publication number
WO1999066909A3
WO1999066909A3 PCT/CA1999/000567 CA9900567W WO9966909A3 WO 1999066909 A3 WO1999066909 A3 WO 1999066909A3 CA 9900567 W CA9900567 W CA 9900567W WO 9966909 A3 WO9966909 A3 WO 9966909A3
Authority
WO
WIPO (PCT)
Prior art keywords
apomorphine
vaginal
hydroxytryptamine
diminished
sexual dysfunction
Prior art date
Application number
PCT/CA1999/000567
Other languages
English (en)
Other versions
WO1999066909A2 (fr
Inventor
Michael A. Adams
Jeremy P. W. Heaton
Original Assignee
Queen's University At Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen's University At Kingston filed Critical Queen's University At Kingston
Priority to AU42547/99A priority Critical patent/AU4254799A/en
Priority to MXPA01000275A priority patent/MXPA01000275A/es
Priority to EP99957146A priority patent/EP1089736A2/fr
Priority to CA002334550A priority patent/CA2334550A1/fr
Priority to JP2000555595A priority patent/JP2002518435A/ja
Publication of WO1999066909A2 publication Critical patent/WO1999066909A2/fr
Publication of WO1999066909A3 publication Critical patent/WO1999066909A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur un procédé de traitement des dysfonctionnements sexuels de la femme dont: les symptômes vasculogènes d'un engorgement vaginal retardé, une lubrification réduite du vagin, des rapports douloureux ou désagréables (dyspareunie), des sensations vaginales réduites, un orgasme vaginal atténué, des sensations clitoridiennes réduites, un orgasme clitoridien atténué, et de combat des douleurs vaginales, en stimulant la libération d'oxyde d'azote par le nerf pelvien périphérique. Le procédé consiste à administrer à la femme le nécessitant une dose à effet thérapeutique d'un composé agissant sur une voie mésencéphalique pour accroître le flux sanguin dans le lit vasculaire des artères iliaques, hypogastriques, et honteuses et stimuler la libération de NO par les cellules des nerfs NANC périphériques. Le composé préféré à cette fin est l'apomorphine ou l'un de ses sels, esters ou précurseurs pharmacocompatibles. Il est également possible d'associer l'apomorphine à une quantité potentialisante d'androgène, de préférence de testostérone, prise soit avant, soit avec l'apomorphine.
PCT/CA1999/000567 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme WO1999066909A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU42547/99A AU4254799A (en) 1998-06-22 1999-06-21 Method and compositions for the treatment or amelioration of female sexual dysfunction
MXPA01000275A MXPA01000275A (es) 1998-06-22 1999-06-21 Metodo y composiciones para el tratamiento o alivio de disfunciones sexuales femeninas.
EP99957146A EP1089736A2 (fr) 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme
CA002334550A CA2334550A1 (fr) 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme
JP2000555595A JP2002518435A (ja) 1998-06-22 1999-06-21 女性の性機能不全の治療または改善のための方法および組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10298798A 1998-06-22 1998-06-22
US09/102,987 1998-06-22

Publications (2)

Publication Number Publication Date
WO1999066909A2 WO1999066909A2 (fr) 1999-12-29
WO1999066909A3 true WO1999066909A3 (fr) 2000-06-29

Family

ID=22292763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000567 WO1999066909A2 (fr) 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme

Country Status (7)

Country Link
EP (1) EP1089736A2 (fr)
JP (1) JP2002518435A (fr)
AR (1) AR019694A1 (fr)
AU (1) AU4254799A (fr)
CA (1) CA2334550A1 (fr)
MX (1) MXPA01000275A (fr)
WO (1) WO1999066909A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
CZ20023637A3 (cs) * 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
FI20002756A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Uusi hoitomenetelmä
CA2440141A1 (fr) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Composes et procedes pour le traitement de desordres urogenitaux
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
GB0204919D0 (en) * 2002-03-01 2002-04-17 Cst Medical Ltd Treatment of female sexual dysfunction
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0172697A2 (fr) * 1984-08-02 1986-02-26 Eli Lilly And Company Octahydro-oxazolo[4,5-g]quinoléines
WO1987004621A1 (fr) * 1986-02-04 1987-08-13 Ekkehard Othmer Traitement du dysfonctionnement sexuel avec de la buspirone
WO1993023035A2 (fr) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0172697A2 (fr) * 1984-08-02 1986-02-26 Eli Lilly And Company Octahydro-oxazolo[4,5-g]quinoléines
WO1987004621A1 (fr) * 1986-02-04 1987-08-13 Ekkehard Othmer Traitement du dysfonctionnement sexuel avec de la buspirone
WO1993023035A2 (fr) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FERRARI, F. ET AL: "Influence of apomorphine on rat female sexual behavior and its relation with induction of stereotypy", RIV. FARMACOL. TER. (1977), 8(4), 355-63, XP002121202 *
GOLDSTEIN I. ET AL: "Vasculogenic female sexual dysfunction: Vaginal engorgement and clitoral erectile insufficiency syndromes.", INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, (1998) 10/SUPPL. 2 (S84-S90)., XP002121200 *
HAMBURGER-BAR, R.; RIGTER, H.: "Apomorphine: Facilitation of sexual behaviour in female rats", EUROPEAN JOURNAL OF PHARMACOLOGY, XP002121204 *
MELIS M.R. ET AL: "Dopamine and sexual behavior.", NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, (1995) 19/1 (19-38)., XP002121203 *
SEGRAVES R.T. ET AL: "Pharmacotherapy for sexual disorders: Advantages and pitfalls.", SEXUAL AND MARITAL THERAPY, (1998) 13/3 (295-309)., XP002121201 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism

Also Published As

Publication number Publication date
AU4254799A (en) 2000-01-10
CA2334550A1 (fr) 1999-12-29
JP2002518435A (ja) 2002-06-25
EP1089736A2 (fr) 2001-04-11
AR019694A1 (es) 2002-03-13
WO1999066909A2 (fr) 1999-12-29
MXPA01000275A (es) 2002-04-24

Similar Documents

Publication Publication Date Title
MXPA00007447A (es) Tratamiento de disfuncion sexual femenina.
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
WO2002051420A3 (fr) Techniques et formulations pour le traitement de dysfonctionnements sexuels chez la femme
WO1999066909A3 (fr) Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
HK1091418A1 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
WO2005013914A8 (fr) Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants
IN2005KO00312A (fr)
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
BG105664A (en) Use of apomophines for the treatment of organic erectile dysfunction in males
SI1305014T1 (sl) Uporaba (deaminohidroksi) toremifena za zdravljenje vaginalne suhosti ali seksualne disfunkcije med menopavzo ali po njej
AU2003274476A1 (en) Treatment of female sexual dysfunction
EP1108426A3 (fr) Utilisation d'agonistes des prostaglandines pour traiter les troubles de l'érection et l'impotence
AU764009B2 (en) Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
NZ512137A (en) Prostaglandin E2 (PGE2) and PGE4 analogues, which are antagonists of the EP2 receptor for treatment of female sexual dysfunction
HK1068003A1 (en) Pharmaceutical composition comprising gamma-butyrobetaine
WO2002041894A3 (fr) Utilisation d'agonistes selectifs des recepteur d4 de la dopamine dans le traitement de dysfonctions sexuelles
DE60030107D1 (de) Vitamin-d derivate zur behandlung des systemischen lupus erythematodes
WO2001000196A3 (fr) Mirtazapine destinee a la prise de poids dans les maladies cachectisantes
AU8906201A (en) Methods and compositions for the treatment and prevention of sexual dysfunction
AU2003204720B2 (en) Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
MY155220A (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
BG106619A (en) Composition of a sedative of an analgetic, suitable in particular in headache and migraine
MY140954A (en) Composition for oral or rectal administration
AU2002352634A1 (en) Compositions for treatment of postmenopausal female sexual dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2334550

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000275

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 42547/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999957146

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999957146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999957146

Country of ref document: EP